Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RPS6KA3 | P51812 | 1/20 | 0.31 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.31 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.31 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.31 |
| ▸ | EGFR | P00533 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10200834 | 0.75 | CCR1 (0.40) | EGFR | |
| SCHEMBL12338376 | 0.75 | LMNA (0.30) | — | |
| SCHEMBL30682141 | 0.75 | CCR1 (0.40) | EGFR | |
| SCHEMBL4569225 | 0.73 | ALDH1A1 (0.40) | EGFR | |
| SCHEMBL12032779 | 0.73 | LMNA (0.31) | — | |
| SCHEMBL24422742 | 0.73 | P2RX3 (0.33) | — | |
| SCHEMBL18779068 | 0.73 | CCR1 (0.42) | GRIN3BGRIN1GRIN2C | |
| SCHEMBL8278971 | 0.72 | KDM4C (0.41) | RPS6KA3EGFR | |
| SCHEMBL27010729 | 0.72 | RPS6KA3 (0.32) | RPS6KA3 | |
| SCHEMBL19250464 | 0.71 | NOS3 (0.31) | EGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023173083-A1 | TETRAHYDROINDOLE DERIVATIVES AS EGFR AND/OR HER2 INHIBTORS USEFUL FOR THE TREATMENT OF CANCER | SCORPION THERAPEUTICS, INC. (US) | 2023-09-14 | — | — | WO | disclosed |
| US-8557848-B2 | 4,5-ring annulated indole derivatives for treating or preventing of HCV and related viral infections | MERCK SHARP & DOHME CORP. (US) | 2013-10-15 | — | — | US | disclosed |
| US-8546420-B2 | 4, 5-ring annulated indole derivatives for treating or preventing of HCV and related viral infections | MERCK SHARP & DOHME CORP. (US) | 2013-10-01 | — | — | US | disclosed |
| US-8268803-B2 | 5, 6-ring annulated indole derivatives and use thereof | MERCK SHARP & DOHME CORP. (US) | 2012-09-18 | — | — | US | disclosed |
| EP-2081922-B1 | 5,6-Ring annulated indole derivatives and use thereof | SCHERING CORP (US) | 2012-02-01 | — | — | EP | disclosed |
| US-20100322901-A1 | 5, 6-RING ANNULATED INDOLE DERIVATIVES AND USE THEREOF | SCHERING CORPORATION | 2010-12-23 | — | — | US | disclosed |
| US-20100196319-A1 | 4, 5-RING ANNULATED INDOLE DERIVATIVES FOR TREATING OR PREVENTING OF HCV AND RELATED VIRAL INFECTIONS | SCHERING CORPORATION (US) | 2010-08-05 | — | — | US | disclosed |
| US-20100196319-A1 | 4, 5-RING ANNULATED INDOLE DERIVATIVES FOR TREATING OR PREVENTING OF HCV AND RELATED VIRAL INFECTIONS | SCHERING CORPORATION (US) | 2010-08-05 | — | — | US | disclosed |
| US-20100098661-A1 | 4,5-RING ANNULATED INDOLE DERIVATIVES FOR TREATING OR PREVENTING OF HCV AND RELATED VIRAL INFECTIONS | SCHERING CORPORATION | 2010-04-22 | — | — | US | disclosed |
| WO-2008082484-A1 | 4,5-RING ANNULATED INDOLE DERIVATIVES FOR TREATING OR PREVENTING OF HCV AND RELATED VIRAL INFECTIONS | SCHERING CORPORATION (US) | 2008-07-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100196319-A1 | 4, 5-RING ANNULATED INDOLE DERIVATIVES FOR TREATING OR PREVENTING OF HCV AND RELATED VIRAL INFECTIONS | ZC3HAV1, IDO1, ZC3HAV1L | RPS6KA3 1562/4885GRIN3B 3027/4885GRIN1 3507/4885 |
| US-20100098661-A1 | 4,5-RING ANNULATED INDOLE DERIVATIVES FOR TREATING OR PREVENTING OF HCV AND RELATED VIRAL INFECTIONS | ZC3HAV1, IDO1, ZC3HAV1L | RPS6KA3 3458/4885GRIN3B 3432/4885GRIN1 3931/4885 |
| US-20100322901-A1 | 5, 6-RING ANNULATED INDOLE DERIVATIVES AND USE THEREOF | IDO1, IDO2, TPH1 | RPS6KA3 3210/4885GRIN3B 1157/4885GRIN1 1616/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.